** H.C. Wainwright starts coverage on biotech firm Virax Biolabs VRAX.O with a "buy" rating and $3 PT, implying a more than twofold upside to stock's last close
** VRAX has an "attractive market opportunity" in post-acute infection syndromes (PAIS) diagnostics, with long COVID potentially contributing to a "hundreds of millions of dollars" market, says brokerage
** PAIS refers to chronic illnesses that occur after an infection, causing prolonged symptoms such as fatigue, pain and cognitive issues
** ViraxImmune, a diagnostic test, is being developed to detect T-cell dysfunction in PAIS, including long COVID, with UK clinical validation study underway, brokerage says
** The test shows promise in evaluating immune status in chronic conditions, with "significant changes" in cytokine levels, which are small proteins that help immune cells communicate, in PAIS patients - H.C. Wainwright
** Over 16 million U.S. and UK patients are affected by long COVID, and 0.5 million may be diagnosed with Lyme disease annually, creating a large market for ViraxImmune - brokerage
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.